Akebia Therapeutics, Inc. (AKBA) Form 8-K — Aug 5, 2026
Akebia Therapeutics reported Q2 2026 total revenues of $49.1 million, down from $62.5 million a year earlier, and swung to a net loss of $8.9 million versus net income of $0.2 million in Q2 2025. The decline was driven by Auryxia falling to $25.5 million from $47.2 million amid generic competition, and the quarter included a $1.9 million commercial restructuring charge. Vafseo was the growth story: net product revenues rose 34% sequentially to $21.3 million (versus $13.3 million in Q2 2025), with more than 10,500 patients on therapy (+41% versus Q1) and roughly 1,200 prescribers (+17% versus Q1).
Key figures
- Revenue
- 49128000
- Guidance
- Existing cash plus expected product, royalty, supply and license revenues and a planned refinancing of the senior secured term loan facility expected to fund the current operating plan for at least two years; Auryxia revenues expected to continue decreasing in 2026 vs 2025 due to generic competition and pricing pressure.
- Revenue Yoy
- -21.4% (derived from stated figures: Q2 2026 $49.1M vs Q2 2025 $62.5M)
- Total Assets
- 349658000
- Cash Position
- 155548000
- Cogs
- $10.4 million (vs $9.9 million in Q2 2025)
- Rd expense
- $14.1 million (vs $11.0 million in Q2 2025)
- Sga expense
- $28.2 million (vs $26.6 million in Q2 2025)
- Voice win odds
- 1.16 (95% CI 1.06, 1.28; p=0.0016)
- Working capital
- $68.7 million as of June 30, 2026
- Vafseo prescribers
- approximately 1,200 (+17% vs Q1 2026)
- Restructuring expense
- $1.9 million
- License collab revenue
- $2.4 million (vs $2.0 million in Q2 2025)
- Vafseo active patients
- more than 10,500 (+41% vs end of Q1 2026)
- Voice trial enrollment
- 2116
- Cash q1 2026 comparison
- $162.6 million as of March 31, 2026
- Vafseo sequential growth
- 34% increase over Q1 2026
- Orange book patents vafseo
- 14
- Vafseo net revenue q2 2025
- $13.3 million
- Vafseo net revenue q2 2026
- $21.3 million
- Auryxia net revenue q2 2026
- $25.5 million (vs $47.2 million in Q2 2025)
- Ebribafusp basket trial size
- up to 30 patients, initial data expected 2027
Price after filing
Close on the filing date to close N calendar days later (from $1.32). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.